Halozyme Therapeutics, Inc. has entered into a global collaboration and license agreement with Incyte to evaluate additional subcutaneous formulations of INCA033989, a mutant calreticulin (mutCALR)-targeted monoclonal antibody. The partnership aims to utilize Halozyme's proprietary ENHANZE drug delivery technology to strengthen the subcutaneous formulation currently in development for INCA033989. The goal is to enable more convenient delivery and dosing regimens that may improve the treatment experience for patients with mutCALR-expressing myeloproliferative neoplasms (MPNs).

Under the terms of the agreement, Halozyme will receive an upfront payment from Incyte and is eligible to receive additional payments upon the achievement of agreed-upon milestones. Furthermore, Halozyme is entitled to receive royalties on net sales of any commercialized medicines that utilize the ENHANZE technology. The collaboration also grants Incyte the option to nominate up to two additional targets for potential use with the ENHANZE platform.

Key Terms of the Agreement

The agreement outlines several financial and strategic components that define the collaboration between Halozyme and Incyte.

The collaboration focuses on leveraging ENHANZE to enhance the subcutaneous delivery of INCA033989. This technology is intended to facilitate more convenient administration, potentially improving patient adherence and overall treatment outcomes in myeloproliferative neoplasms.

Halozyme Therapeutics, Inc. confirmed on June 15, 2026, that it expects zero to minimal impact on its royalty revenues through at least 2035 based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program issued by the U.S. Centers for Medicare & Medicaid Services (CMS) on June 12, 2026. The company's analysis indicates that the statutory framework established under the One Big Beautiful Bill Act (OBBBA) safeguards its financial outlook. Consequently, Halozyme stated there is no projected impact on its capacity to execute new ENHANZE partnership agreements, as improving patient treatment experience and competitive differentiation remain primary drivers for the technology's utilization.

Analysis of the Proposed Rule

The company's assessment relies on specific provisions within the CMS proposal. The rule affirms that orphan drug protections remain applicable, a critical factor for Halozyme's revenue projections. Additionally, the proposal addresses the impacts of biosimilar entry on Program eligibility, further supporting the company's stance that its royalty streams are secure.

Strategic Outlook and Engagement

Dr. Helen Torley, President and Chief Executive Officer of Halozyme, emphasized that the analysis confirms the durability of the company's business model despite regulatory changes. She highlighted that the core value propositions of ENHANZE—improving patient experience and providing competitive differentiation—continue to drive partnerships. Halozyme plans to maintain constructive engagement with CMS and other stakeholders to advocate for policies that recognize innovation and preserve patient access to therapies that improve outcomes and reduce the overall burden on the healthcare system.